- The preliminary efficacy data reported in this presentation are results by investigator assessment.
- Only patients enrolled ≥ 13 weeks prior to the data cutoff date (16 June 2023) were included in the efficacy analysis.
- All patients who received ≥ 1 dose of study treatment were included in the safety analysis.
Results
- At data cutoff (16 June 2023), median (range) follow-up for Cohorts A and B was 5.0 (1.7-12.0) and 5.8 (1.0-12.2) months, respectively
- Across both cohorts, the most common reason for discontinuation of sacituzumab govitecan was progressive disease
- The most common any-grade TEAEs were diarrhea (54%), anemia (48%), and asthenia (38%)
- Immune-mediated TEAEs were consistent with the known safety profile of pembrolizumab.
Conclusions
- SG + Pembro demonstrated encouraging antitumor activity in patients with 1L mNSCLC across PD-L1 subgroups.
- ORR was 69% and DCR was 86% in Cohort A
- ORR was 44% and DCR was 78% in Cohort B
- Median DOR was not reached, and DOR rate at 6 months was 88% in both cohorts.
- The safety profile of SG + Pembro was manageable and consistent with the known safety of each agent.
- The most common any-grade TEAEs were diarrhea, anemia, and asthenia
- TEAEs leading to treatment discontinuation were low (18%)
- These preliminary results warrant further investigation of SG + Pembro for the 1L treatment of mNSCLC
- The ongoing, open-label, global, randomized, phase 3 EVOKE-03 study (NCT05609968) is evaluating SG + Pembro versus Pembro monotherapy in patients with untreated 1L mNSCLC with PD-L1 TPS ≥ 50%
Cho BC, Cobo Dols M, Reyes Cabanillas R, et al. Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non–Small Cell Lung Cancer: Preliminary Results of the EVOKE-02 Study. Abstract presented at: World Conference on Lung Cancer, September 9-12, 2023.